Recent Advances in Small Molecule and Biological Therapeutic Approaches in the Treatment of Psoriasis.

作者: JG Turbeville , NU Patel , LA Cardwell , E Oussedik , SR Feldman

DOI: 10.1002/CPT.688

关键词:

摘要: New treatments continue to be developed for psoriasis. In this review, we aim summarize the results of major published studies on biologic and small molecule drugs treatment We emphasize safety, efficacy, tolerability these options. A review MEDLINE database was conducted each class medication. Randomized controlled trials were identified medication; data reviewed. Biologic options are more effective than placebo, although there few head-to-head assess relative efficacy between biologics treatments. These offer favorable safety profiles with only rare serious adverse events reported. diverse therapeutic regimens, particularly in patients recalcitrant disease.

参考文章(80)
Tushar S Dabade, Steven R Feldman, Shawn G Kwatra, Cheryl J Gustafson, JAK inhibitors in psoriasis: a promising new treatment modality. Journal of Drugs in Dermatology. ,vol. 11, pp. 913- 918 ,(2012)
Green A, Brandrup F, The prevalence of psoriasis in Denmark. Acta Dermato-venereologica. ,vol. 61, pp. 344- ,(1981)
Nannie Bangsgaard, Christina Rørbye, Lone Skov, Treating Psoriasis During Pregnancy: Safety and Efficacy of Treatments. American Journal of Clinical Dermatology. ,vol. 16, pp. 389- 398 ,(2015) , 10.1007/S40257-015-0137-5
D. Gladman, R. Fleischmann, G. Coteur, F. Woltering, P. J. Mease, Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24‐Week Patient‐Reported Outcome Results of a Phase III, Multicenter Study Arthritis Care and Research. ,vol. 66, pp. 1085- 1092 ,(2014) , 10.1002/ACR.22256
K. Reich, J.-P. Ortonne, A.B. Gottlieb, I.J. Terpstra, G. Coteur, C. Tasset, P. Mease, Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension British Journal of Dermatology. ,vol. 167, pp. 180- 190 ,(2012) , 10.1111/J.1365-2133.2012.10941.X
A Maza, H Montaudié, E Sbidian, A Gallini, S Aractingi, F Aubin, H Bachelez, B Cribier, P Joly, D Jullien, M Le Maître, L Misery, M-A Richard, J-P Ortonne, C Paul, Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis Journal of the European Academy of Dermatology and Venereology. ,vol. 25, pp. 19- 27 ,(2011) , 10.1111/J.1468-3083.2011.03992.X
K.A. Papp, M.A. Menter, M. Abe, B. Elewski, S.R. Feldman, A.B. Gottlieb, R. Langley, T. Luger, D. Thaci, M. Buonanno, P. Gupta, J. Proulx, S. Lan, R. Wolk, , Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Results from two randomized, placebo-controlled, phase III trials British Journal of Dermatology. ,vol. 173, pp. 949- 961 ,(2015) , 10.1111/BJD.14018